Desphospho-uncarboxylated matrix Gla-protein is associated with mortality risk in patients with chronic stable vascular disease
Jazyk angličtina Země Irsko Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
24835435
DOI
10.1016/j.atherosclerosis.2014.04.027
PII: S0021-9150(14)00227-5
Knihovny.cz E-zdroje
- Klíčová slova
- Coronary heart disease, Dp-cMGP, Dp-ucMGP, EUROASPIRE, Matrix Gla-protein, Mortality, Secondary prevention, Stroke,
- MeSH
- biologické markery krev MeSH
- cévní mozková příhoda krev mortalita MeSH
- ELISA MeSH
- extracelulární matrix - proteiny krev chemie MeSH
- infarkt myokardu krev mortalita MeSH
- ischemická choroba srdeční krev mortalita MeSH
- Kaplanův-Meierův odhad MeSH
- kardiovaskulární nemoci krev diagnóza MeSH
- lidé středního věku MeSH
- lidé MeSH
- matrixový protein Gla MeSH
- nemoci cév krev mortalita MeSH
- proporcionální rizikové modely MeSH
- prospektivní studie MeSH
- proteiny vázající vápník krev chemie MeSH
- regresní analýza MeSH
- revaskularizace myokardu mortalita MeSH
- senioři MeSH
- vitamin K metabolismus MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- biologické markery MeSH
- extracelulární matrix - proteiny MeSH
- proteiny vázající vápník MeSH
- vitamin K MeSH
BACKGROUND: Vitamin K is the essential co-factor for activation of matrix Gla-protein (MGP), the natural inhibitor of tissue calcification. Biologically inactive, desphospho-uncarboxylated MGP (dp-ucMGP) is a marker of vascular vitamin K status and is described to predict mortality in patients with heart failure and aortic stenosis. We hypothesized that increased dp-ucMGP might be associated with mortality risk in clinically stable patients with chronic vascular disease. MATERIALS AND METHODS: We examined 799 patients (mean age 65.1 ± 9.3 years) who suffered from myocardial infarction, coronary revascularization or first ischemic stroke (pooled Czech samples of EUROASPIRE III and EUROASPIRE-stroke surveys), and followed them in a prospective cohort study. To estimate the 5-year all-cause and cardiovascular mortality we ascertained vital status and declared cause of death. Circulating dp-ucMGP and desphospho-carboxylated MGP (dp-cMGP) were measured by ELISA methods (IDS and VitaK). RESULTS: During a median follow-up of 2050 days (5.6 years) 159 patients died. In the fully adjusted multivariate Cox proportional hazard model, the patients in the highest quartile of dp-ucMGP (≥ 977 pmol/L) had higher risk of all-cause and cardiovascular 5-year mortality [HRR 1.89 (95% CI, 1.32-2.72) and 1.88 (95% CI, 1.22-2.90)], respectively. Corresponding HRR for dp-cMGP were 1.76 (95% CI, 1.18-2.61) and 1.79 (95% CI, 1.12-2.57). CONCLUSIONS: In patients with overt vascular disease, circulating dp-ucMGP and dp-cMGP were independently associated with the risk of all-cause and cardiovascular mortality. Since published results are conflicting regarding the dp-cMGP, we propose only circulating dp-ucMGP as a potential biomarker for assessment of additive cardiovascular risk.
Department of Neurology University Hospital Pilsen Czech Republic
VitaK Cardiovascular Research Institute Maastricht Maastricht University The Netherlands
Citace poskytuje Crossref.org
